Treating asthma as an inflammatory disease
Treating asthma as an inflammatory disease
复制标题
DOI：
10.1378/chest.130.1_suppl.21s
复制
发表时间：
2006-07-01
期刊：
影响因子：
9.6
通讯作者：
Canonica, G. Walter
中科院分区：
文献类型：
--
作者：
Canonica, G. Walter
哮喘是一种慢性炎症性疾病，涉及许多不同的细胞类型和细胞成分。有证据表明，从长期来看，这种炎症会导致气道重塑、气流阻塞和哮喘的支气管高反应性症状，甚至在间歇性疾病患者中也存在。过敏性哮喘患者和季节性变应性鼻炎患者被认为具有最小的持续性炎症，并且这两种疾病经常同时发生。吸入皮质类固醇（ICS）的早期干预被认为可以改变疾病的进程，并可能限制长期的重塑。ICS仍然是哮喘治疗的基石和“金标准”。
Asthma is a chronic inflammatory disease involving many different cell types and cellular elements. Evidence suggests that, in the long term, this inflammation leads to remodeling of the airways, airflow obstruction, and the bronchial hyperreactivity symptoms of asthma, and is present even in patients with intermittent disease. Patients with allergic asthma and those with seasonal allergic rhinitis are believed to have minimal persistent inflammation, and the two diseases often occur together. Early intervention with inhaled corticosteroids (ICS) is believed to modify the disease process and may limit long-term remodeling. ICS remain the Cornerstone and "gold standard" of treatment for asthma.